FR2704395A1 - Nutritional supplement which can be taken by mouth, intended for improving mental activity - Google Patents
Nutritional supplement which can be taken by mouth, intended for improving mental activity Download PDFInfo
- Publication number
- FR2704395A1 FR2704395A1 FR9305319A FR9305319A FR2704395A1 FR 2704395 A1 FR2704395 A1 FR 2704395A1 FR 9305319 A FR9305319 A FR 9305319A FR 9305319 A FR9305319 A FR 9305319A FR 2704395 A1 FR2704395 A1 FR 2704395A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- intended
- nutritional supplement
- methionine
- choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 11
- 230000003340 mental effect Effects 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229930182817 methionine Natural products 0.000 claims abstract description 7
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims abstract description 6
- 239000004381 Choline salt Substances 0.000 claims abstract 2
- 235000019417 choline salt Nutrition 0.000 claims abstract 2
- 150000003248 quinolines Chemical class 0.000 claims abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 229960001231 choline Drugs 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 239000008347 soybean phospholipid Substances 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- RPERJPYDELTDMR-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RPERJPYDELTDMR-UHFFFAOYSA-K 0.000 claims description 4
- 229960003257 choline citrate Drugs 0.000 claims description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003761 Vitamin B9 Natural products 0.000 claims description 3
- 230000007177 brain activity Effects 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 229960004441 tyrosine Drugs 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
COMPLEMENT NUTRITIONNEL ABSORBABLE PER-OS DESTINE A
AMELIORER L'ACTIVISTE CEREBRALE.PER-OS ABSORBABLE NUTRITIONAL SUPPLEMENT FOR A
IMPROVE THE BRAIN ACTIVIST.
L'invention vise un complément nutritionnel absorbable per-os destiné à améliorer l'activité cérébrale, notamment la concentration et la mémorisation. The invention relates to an absorbable per-bone nutritional supplement intended to improve brain activity, in particular concentration and memorization.
Dans une forme de réalisation pratique, ce complément nutritionnel absorbable est utilisé pour compenser les carences alimentaires et optimiser le fonctionnement intellectuel. In a practical embodiment, this absorbable nutritional supplement is used to compensate for nutritional deficiencies and optimize intellectual functioning.
Par "complément nutritionnel", on désigne un ensemble absorbable formant une supplémentation en micronutriments, complétant l'alimentation quotidienne, qui permet à la fois d'agir sur un symptôme et en même temps de renforcer l'organisme. By "nutritional supplement" is meant an absorbable whole forming a micronutrient supplementation, supplementing the daily diet, which allows both to act on a symptom and at the same time to strengthen the organism.
Comme on le sait, les déficiences alimentaires, notamment en oligoéléments, en vitamines, en acides aminés ou en acides gras polyinsaturés, se traduisent souvent par des fatigues physiques ou par une sensation d'inconfort (baisses de la forme intellectuelle et morale), pouvant parfois malheureusement aboutir à des troubles fonctionnels ou des maladies spécifiques. As we know, dietary deficiencies, especially in trace elements, vitamins, amino acids or polyunsaturated fatty acids, often result in physical fatigue or a feeling of discomfort (reduced intellectual and moral form), which can sometimes unfortunately lead to functional disorders or specific diseases.
L'invention vise à pallier ces inconvénients. Elle concerne un complément nutritionnel absorbable per-os, qui améliore efficacement l'activité cérébrale en rééquilibrant l'ensemble de l'organisme. The invention aims to overcome these drawbacks. It relates to an absorbable per-bone nutritional supplement, which effectively improves brain activity by rebalancing the entire body.
Ce complément se caractérise en ce qu'il contient de la tyrosine, au moins un sel de la choline, une association de vitamines B, de la méthionine et un excipient. This supplement is characterized in that it contains tyrosine, at least one salt of choline, a combination of B vitamins, methionine and an excipient.
Comme on le sait:
- la tyrosine est un amino-acide aromatique, dont la fonction -NH2 est bloquée par amidification, notamment acétyle ou propionyle; c'est à partir de cet acide aminé qu'est synthétisée la noradrénaline, neurotransmetteur impliqué dans le phénomène de la concentration;
- la choline est la molécule à partir de laquelle est synthétisée l'acétylcholine, neurotransmetteur impliqué dans le phénomène de mémorisation ; ce composé est présent dans la lécithine de soja, notamment sous forme de phosphatidylcholine;
- la méthionine est un amino-acide aliphatique soufré, qui contribue à la synthèse de l'acétylcholine;
- les vitamines B, notamment BI, B6 , B9 et B12 comme la
L-méthionine, optimisent la transformation de la L-tyrosine et de la choline, respectivement en noradrénaline et en acétylcholine.As we know:
- Tyrosine is an aromatic amino acid, the -NH2 function of which is blocked by amidification, in particular acetyl or propionyl; it is from this amino acid that norepinephrine, the neurotransmitter involved in the phenomenon of concentration, is synthesized;
- choline is the molecule from which acetylcholine, the neurotransmitter involved in the memorization phenomenon, is synthesized; this compound is present in soy lecithin, in particular in the form of phosphatidylcholine;
- methionine is a sulfur-containing aliphatic amino acid, which contributes to the synthesis of acetylcholine;
- vitamins B, in particular BI, B6, B9 and B12 such as
L-methionine, optimize the transformation of L-tyrosine and choline, respectively into norepinephrine and acetylcholine.
Avantageusement, en pratique
- la tyrosine et la méthionine sont sous forme L;
- la source de choline est issue du citrate de choline et de la lécithine de soja;
- l'association de vitamines B comprend dans l'ordre pondéral décroissant: de la vitamine B6, B1, B9 et B12;
- l'excipient comprend du dextrose, de la cellulose et du stéarate de magnésium (agent liant et lubrifiant). Advantageously, in practice
- tyrosine and methionine are in L form;
- the source of choline comes from choline citrate and soy lecithin;
- the association of vitamins B comprises in decreasing weight order: vitamin B6, B1, B9 and B12;
- the excipient includes dextrose, cellulose and magnesium stearate (binding and lubricating agent).
En d'autres termes, l'invention vise une association, qui non seulement optimise la transformation, respectivement de la L-tyrosine en noradrénaline et de la choline en acétylcholine, mais également optimise les propriétés neurotransmettrices de la noradrénaline et de l'acétylcholine, et ce dans les meilleures conditions possibles. In other words, the invention relates to a combination which not only optimizes the transformation, respectively of L-tyrosine into noradrenaline and choline into acetylcholine, but also optimizes the neurotransmitter properties of noradrenaline and acetylcholine, and this in the best possible conditions.
Dans une forme de réalisation pratique, le complément nutritionnel conforme à l'invention contient en poids en pour cent:
- 40 % de citrate de choline
- 5 % d'une lécithine de soja contenant de 30 à 35 % de phosphatidylcholine;
-18 % de L tyrosine;
-10 % de L méthionine L méthionine;
- 0,1 % de vitamine B6;
- 0,07 % de vitamine B1;
- 0,01 % de vitamine B9;
- 0,00005 % de vitamine B12;
- 26,82 % d'excipient, par exemple:
. 19 % de dextrose;
.5,82% de cellulose;
. 2 % de stéarate de magnésium. In a practical embodiment, the nutritional supplement according to the invention contains by weight in percent:
- 40% choline citrate
- 5% of a soy lecithin containing from 30 to 35% of phosphatidylcholine;
-18% L tyrosine;
-10% of L methionine L methionine;
- 0.1% vitamin B6;
- 0.07% vitamin B1;
- 0.01% vitamin B9;
- 0.00005% vitamin B12;
- 26.82% of excipient, for example:
. 19% dextrose;
5.82% cellulose;
. 2% magnesium stearate.
Pour garantir l'intégrité des différents composés, on effectue avantageusement la formulation de la manière suivante. Dans un premier temps, on granule en phase humide les excipients et les principaux composés. Puis, dans un deuxième temps, on mélange en phase sèche les vitamines et les principes actifs fragiles. To guarantee the integrity of the various compounds, the formulation is advantageously carried out in the following manner. Initially, the excipients and the main compounds are granulated in the wet phase. Then, in a second step, vitamins and fragile active ingredients are mixed in the dry phase.
Le complément nutritionnel conforme à l'invention se présente sous forme sèche, notamment sous forme de granules, de gélules, de poudre, et avantageusement de comprimés, etc
Cette préparation peut facilement être absorbée lorsque les fonctions intellectuelles, telles que la concentration et la mémoire sont particulièrement sollicitées, notamment pour faire face à une augmentation particulière de la demande, comme c'est parfois le cas chez les étudiants ou les adultes. Elle permet également de relancer essentiellement le fonctionnement des neurones chez les personnes qui observent parfois un manque de concentration et une baisse des capacités de mémorisation.The nutritional supplement according to the invention is in dry form, in particular in the form of granules, capsules, powder, and advantageously tablets, etc.
This preparation can easily be absorbed when intellectual functions, such as concentration and memory are particularly stressed, in particular to cope with a particular increase in demand, as is sometimes the case in students or adults. It also essentially boosts the functioning of neurons in people who sometimes observe a lack of concentration and a decline in memory capacity.
Ce complément nutritionnel, sous la forme de comprimés de 500 mg, peut être avalé à raison de quatre comprimés le matin à jeun pendant deux à trois mois, à renouveler suivant les besoins. This nutritional supplement, in the form of 500 mg tablets, can be swallowed at the rate of four tablets in the morning on an empty stomach for two to three months, to be renewed as needed.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305319A FR2704395B1 (en) | 1993-04-29 | 1993-04-29 | Oral absorbable nutritional supplement intended to improve brain activity. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305319A FR2704395B1 (en) | 1993-04-29 | 1993-04-29 | Oral absorbable nutritional supplement intended to improve brain activity. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2704395A1 true FR2704395A1 (en) | 1994-11-04 |
| FR2704395B1 FR2704395B1 (en) | 1995-06-02 |
Family
ID=9446746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9305319A Expired - Fee Related FR2704395B1 (en) | 1993-04-29 | 1993-04-29 | Oral absorbable nutritional supplement intended to improve brain activity. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2704395B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19731432A1 (en) * | 1997-07-22 | 1999-02-04 | Phoenix Lab Pharmazeutische Pr | Use of choline citrate to treat CNS disorders |
| WO2008067640A1 (en) * | 2006-12-06 | 2008-06-12 | H3 Formulations Ltd. | Composition for promoting cognitive attributes |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB992956A (en) * | 1960-06-02 | 1965-05-26 | Gustave Marie Joseph Boucher | Pharmaceutical preparations containing pyrrolidone carboxylic acid and salts and esters thereof |
| US4837219A (en) * | 1987-11-05 | 1989-06-06 | Jeffrey Hutterer | Medication for Alzheimer's disease |
| JPH02212421A (en) * | 1989-02-10 | 1990-08-23 | Masaki Imagawa | Remedy for dementia |
| JPH02265457A (en) * | 1989-04-04 | 1990-10-30 | Nikken Food Kk | Auxiliary food of brain nutrition |
| JPH0494669A (en) * | 1990-08-08 | 1992-03-26 | Q P Corp | Composition for healthy brain |
-
1993
- 1993-04-29 FR FR9305319A patent/FR2704395B1/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB992956A (en) * | 1960-06-02 | 1965-05-26 | Gustave Marie Joseph Boucher | Pharmaceutical preparations containing pyrrolidone carboxylic acid and salts and esters thereof |
| US4837219A (en) * | 1987-11-05 | 1989-06-06 | Jeffrey Hutterer | Medication for Alzheimer's disease |
| JPH02212421A (en) * | 1989-02-10 | 1990-08-23 | Masaki Imagawa | Remedy for dementia |
| JPH02265457A (en) * | 1989-04-04 | 1990-10-30 | Nikken Food Kk | Auxiliary food of brain nutrition |
| JPH0494669A (en) * | 1990-08-08 | 1992-03-26 | Q P Corp | Composition for healthy brain |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI Week 9040, Derwent World Patents Index; AN 90-301255 * |
| DATABASE WPI Week 9049, Derwent World Patents Index; AN 90-366299 * |
| DATABASE WPI Week 9219, Derwent World Patents Index; AN 92-156043 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19731432A1 (en) * | 1997-07-22 | 1999-02-04 | Phoenix Lab Pharmazeutische Pr | Use of choline citrate to treat CNS disorders |
| DE19731432C2 (en) * | 1997-07-22 | 1999-07-15 | Phoenix Lab Pharmazeutische Pr | Use of choline citrate |
| WO2008067640A1 (en) * | 2006-12-06 | 2008-06-12 | H3 Formulations Ltd. | Composition for promoting cognitive attributes |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2704395B1 (en) | 1995-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5911992A (en) | Method for controlling weight with hypericum perforatum and garcinia cambogia | |
| RU2152216C1 (en) | Composition containing dietetic additives (versions) | |
| EP0007691B1 (en) | Compositions for use in decreasing appetite for calories as carbohydrates | |
| US20020155163A1 (en) | Integrated multi-vitamin and mineral combination | |
| WO2002032234A1 (en) | Anti-stress composition designed to be mainly incorporated in nutritional carriers | |
| EA015422B1 (en) | Combination preparation for improving sperm quality | |
| KR20010071467A (en) | Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects | |
| US6218420B1 (en) | Compositions based on aminoacids | |
| US6447818B1 (en) | Compositions containing compounds with adrenergic activity and vegetable extracts of Crataegus and gingko biloba for the treatment of overweight and obesity | |
| JP2001518484A (en) | Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and for preventing abuse of alcohol in healthy people | |
| MXPA06001706A (en) | Multivitamin syrup for children or young adults. | |
| FR2704395A1 (en) | Nutritional supplement which can be taken by mouth, intended for improving mental activity | |
| FR2704393A1 (en) | Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones | |
| WO1995005146A1 (en) | Composition against hair loss and brittle nails | |
| FR2704392A1 (en) | Nutritional supplement which can be taken orally to improve and optimise individuals' levels of physical and mental activity | |
| EP0349143B1 (en) | Use of phytic acid or its salts for the prevention or treatment of hepatic diseases | |
| CA3113821A1 (en) | Leucine-enriched ketogenic formulations | |
| FR2737849A1 (en) | Orally administered food supplement for adults of over forty | |
| FR2886154A1 (en) | COMPOSITION FOR DELAYING THE DEVELOPMENT OF ALZHEIMER'S DISEASE | |
| WO2022013581A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
| FR2704391A1 (en) | Nutritional supplement which can be taken orally to facilitate adaptation to daily stress | |
| Wilcken | An Introduction to Nutritional Treatment in Inborn Errors of Metabolism-Different Disorders, Different Approaches | |
| JPS61192264A (en) | Food | |
| Dickerson | Some adverse effects of drugs on nutrition | |
| KR100309715B1 (en) | Composition having function for preventing toxicity and hangover of alcohol by activation of citric acid cycle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |